Toward victory in adult ALL: Blinatumomab joins in

Blood

Volumn 120, Issue 26, 2012, Pages 5094-5095

  Bassan, Renato ^a  

^a OSPEDALE DELL'ANGELO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; INOTUZUMAB OZOGAMICIN; MERCAPTOPURINE; METHOTREXATE; RITUXIMAB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; HUMAN; MINIMAL RESIDUAL DISEASE; NEUROTOXICITY; NOTE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR MICROENVIRONMENT;

EID: 84871512625     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-10-460394     Document Type: Note

References (10)

1. Topp MS, Gokbuget N, Zugmaier G, et al. Long-term follow-up of hematological relapse-free survival in a phase 2 study of blinatumomab in patients with minimal residual disease (MRD) of B-precursor acute lymphoblastic leukemia (ALL). Blood. 2012;120(26):5185-5187.
2. Bargou R, Leo E, Zugmaier G, et al. Tumor regression in cancer patients by very low doses of aTcell-engaging antibody. Science. 2008;321(5891):974-977.
3. Rowe J. Prognostic factors in adult acute lymphoblastic leukemia. Br J Haematol. 2010;150(4):389-405.
4. Bassan R, Spinelli O, Oldani E, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009;113(18):4153- 4162.
5. Gökbuget N, Kneba M, Raff T, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120(9):1868-1876.
6. Topp MS, Gökbuget N, Zugmaier G, et al. Anti-CD19 BiTE Blinatumomab induces high complete remissione rate and prolongues survival in adult patients with relapsed/refractory B-precursore acute lymphoblastic leukemia (ALL). Haematologica. 2012;97(Suppl 1):462.
7. Henderson E. Acute lymphocytic leukemia. In: Gunz FW, Henderson ES, eds. Leukemia. New York, NY: Grune & Stratton; 1983:575-625.
8. Hoelzer D. Novel antibody-based therapies for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2011;2011:243-249.
9. Kantarjian H, Thomas D, Wayne AS, O'Brien S. Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia. J Clin Oncol. 2012;30(31):3876-3883.
10. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011;29(5):532-543.